---
title: "SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292772090.md"
description: "SciSparc Ltd. announced that its subsidiary, NeuroThera Labs Inc., has initiated a Phase IIb clinical trial at Hannover Medical School in Germany. The trial evaluates SCI-110, a cannabinoid-based treatment for Tourette Syndrome in adults. This development marks a significant advancement in researching therapies for the disorder."
datetime: "2026-07-15T12:43:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292772090.md)
  - [en](https://longbridge.com/en/news/292772090.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292772090.md)
generator: "portal-rs"
---

# SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

TEL AVIV, Israel, July 15, 2026 - SciSparc Ltd. revealed that its branch NeuroThera Labs Inc. has started its Phase IIb clinical trial site at Hannover Medical School in Hanover, Germany for SCI-110, a cannabinoid-based treatment for Tourette Syndrome in adults. NeuroThera Labs, a clinical-stage pharmaceutical company under SciSparc, is dedicated to developing innovative therapies for central nervous system conditions. The commencement of the trial marks a significant advancement in the research for treating TS, and signifies a crucial step towards potentially offering relief to those affected by the disorder.

### Related Stocks

- [SPRC.US](https://longbridge.com/en/quote/SPRC.US.md)

## Related News & Research

- [SciSparc’s NeuroThera Advances Enrollment in SCI-210 Autism Trial](https://longbridge.com/en/news/297830603.md)
- [SciSparc subsidiary NeuroThera Labs enrolls 26 children in SCI-210 autism trial](https://longbridge.com/en/news/297556067.md)
- [Weekly Recap: 370,000-Share Buyback and Raymond James Market Perform](https://longbridge.com/en/news/297508692.md)
- [Half of VW's job cuts will be in Germany, supervisory board member says](https://longbridge.com/en/news/298022093.md)
- [FDA approves PharmaEssentia BESREMi for adults with essential thrombocythemia](https://longbridge.com/en/news/297513690.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**